肺纤维化合并肺气肿的HRCT影像表型、临床特征与预后
回顾性纳入383例肺纤维化-肺气肿综合征(CPFE)患者,按HRCT定量分为肺气肿为主型(CPFE-E,n=96)和纤维化为主型(CPFE-F,n=287)。CPFE-E组男性比例、吸烟指数、支气管舒张剂使用率及肺气肿占比更高,糖尿病患病率更低;整体随访期间两组远期生存无显著差异,但肺气肿占比每增加1%使CPFE-E组死亡风险升高6%。
要点
- CPFE可依HRCT定量分为肺气肿为主型与纤维化为主型,两型临床特征异质。
- 肺气肿占比是CPFE-E组预后的独立危险因素,每增加1%死亡风险升高6%。
- 纤维化占比仅在CPFE-E组显著增加死亡风险(HR=1.24)。
核心结论
- CPFE影像表型可分为CPFE-E与CPFE-F两型,呈现明显异质性。
- 肺气肿占比是CPFE-E组预后的独立危险因素。
- 基于亚型的个体化管理可能改善临床结局。
研究设计与样本
- 回顾性纳入来自3家三甲医院的383例CPFE患者。
- 按HRCT定量肺气肿与纤维化全肺容积占比分组:CPFE-E组96例(男90例,中位年龄65岁),CPFE-F组287例(男230例,中位年龄65岁)。
- 比较临床特征、治疗方案及生存率(Kaplan-Meier法),采用Cox回归估计风险比(HR)及95%CI。
主要发现
- CPFE-E组肺气肿占比中位数12%高于CPFE-F组的1%(W=24 101.00,P<0.001)。
- CPFE-E组男性比例93.8%高于80.1%(χ²=9.70,P=0.002),吸烟指数650包年高于400包年(W=16 049.50,P=0.014),支气管舒张剂使用率39.6%高于22.0%(χ²=11.52,P<0.001)。
- CPFE-E组糖尿病患病率6.3%低于18.5%(χ²=8.24,P=0.004)。
- CPFE-E组2年病死率18.8%(18/96)高于CPFE-F组的17.8%(51/287);整体随访(中位390 d)两组远期生存趋势无显著差别(21.9%比20.2%,log-rank P=0.594)。
- 多因素分析示肺气肿占比每增加1%使CPFE-E组死亡风险升高6%(HR=1.06,95%CI:1.04~1.08,P<0.001),纤维化占比仅在CPFE-E组显著增加死亡风险(HR=1.24,95%CI:1.15~1.33,P<0.001)。
临床怎么用
- 临床可依据HRCT定量肺气肿与纤维化占比对CPFE进行亚型划分。
- 对CPFE-E型应关注肺气肿占比,其与死亡风险升高相关。
- 亚型导向的个体化管理可能有助于改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the high-resolution CT (HRCT) imaging phenotypes, clinical characteristics and prognostic differences between emphysema-dominant (CPFE-E) and fibrosis-dominant (CPFE-F) subtypes of combined pulmonary fibrosis and emphysema (CPFE). Methods: A retrospective study of 383 CPFE patients was retrospectively enrolled. Based on quantitative HRCT analysis of emphysema and fibrosis proportions, patients were classified into CPFE-E group (emphysema proportion>fibrosis proportion, n=96; 90 men; median age 65 years) and CPFE-F group (fibrosis proportion>emphysema proportion, n=287; 230 men; median age 65 years). Clinical features, treatment regimens, and survival rates (Kaplan-Meier method) were compared, with Cox regression estimating Hazard ratio (HR) and 95%CI of emphysema/fibrosis subtypes on all-cause mortality. Results: The CPFE-E group had higher median emphysema proportion (12% vs. 1%, W=24 101.00, P<0.001), male predominance (93.8% vs. 80.1%, χ²=9.70, P=0.002), smoking index (650 vs. 400 pack-years, W=16 049.50, P=0.014), and bronchodilator use (39.6% vs. 22.0%, χ²=11.52, all P<0.001), but lower diabetes prevalence (6.3% vs. 18.5%, χ²=8.24, P=0.004). Survival analysis revealed lower 2-year survival in CPFE-E (18/96 vs. 51/287); however, the long-term survival trend over the entire follow-up period (median, 390 days) showed no significant difference between the two groups (21/96 vs. 58/287, log-rank P=0.594). Multivariate Cox regression showed that each 1% increase in emphysema proportion was associated with a 6% increase in mortality risk in the CPFE-E group (adjusted HR=1.06, 95%CI: 1.04-1.08, P<0.001), whereas fibrosis proportion significantly increased mortality risk only in CPFE-E (HR=1.24, 95%CI:1.15-1.33, P<0.001). Conclusion: CPFE imaging phenotypes can be classified into CPFE-E and CPFE-F, which show marked heterogeneity. Emphysema proportion is an independent risk factor for prognosis in CPFE-E group. Subtype-oriented individualized management may improve clinical outcomes. 目的: 探讨肺纤维化-肺气肿综合征(CPFE)的患者高分辨率CT(HRCT)影像学表型、临床特征及预后差异。 方法: 回顾性纳入来自3家三甲医院的383例CPFE患者,根据HRCT定量分析纤维化与肺气肿全肺容积占比进行影像表型分组:肺纤维化与肺气肿占比差值≤0的96例患者纳入肺气肿为主型(CPFE-E)组,其中男90例,女6例,中位年龄65岁;肺纤维化与肺气肿占比差值>0的287例患者纳入肺纤维化为主型(CPFE-F)组,其中男230例,女57例,中位年龄65岁。比较2组的临床特征、治疗方案及生存率(Kaplan-Meier法),采用Cox回归估计肺气肿/纤维化占比与全因病死率的风险比(HR)及95%置信区间(CI)。 结果: 与CPFE-F组相比,CPFE-E组男性比例(93.8% 比 80.1%,χ²=9.70,P=0.002)、吸烟指数(650包年比 400包年,W=16 049.50,P=0.014)及支气管舒张剂使用率(39.6% 比 22.0%,χ²=11.52,P<0.001)更高,糖尿病患病率更低(6.3% 比18.5%,χ²=8.24,P=0.004),肺气肿占比中位数更高(12% 比 1%,W=24 101.00,P<0.001),差异均有统计学意义。生存曲线显示,CPFE-E组2年病死率高于CPFE-F组[18.8%(18/96)比17.8%(51/287)];但整体随访期间(中位时间390 d),两组远期生存趋势无明显差别[21.9%(21/96)比20.2%(58/287),log-rank检验P=0.594]。多因素分析结果表明,肺气肿占比每增加1%使CPFE-E组死亡风险升高6%(HR=1.06,95%CI:1.04~1.08,P<0.001),而纤维化占比仅在CPFE-E组显著增加死亡风险(HR=1.24,95%CI:1.15~1.33,P<0.001)。 结论: CPFE并非均一整体,HRCT定量影像表型CPFE-E型和CPFE-F型决定了患者的疾病总负荷与早期预后轨迹,区分不同亚型对临床制定个体化的抗纤维化治疗策略具有重要指导价值。.
引用
- Wang HY, Wang S, He JR, et al. [High-resolution CT imaging phenotypes, clinical characteristics, and prognosis in patients with combined pulmonary fibrosis and emphysema]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42557070. doi:10.3760/cma.j.cn112147-20251222-00812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。